HK Recently Listed Stocks Watch | ALEBUND-B (09637.HK): 1H Revenue Up 761.2% YoY, 28.2549 Million Cornerstone Lock-up Shares to Be Unlocked on December 29

NewTimeSpace News: On October 16, 2026, ALEBUND-B (09637.HK) traded weakly, with the company quoting HKD 17.96 as of 15:15, down 3.54%.

On the news front, according to previous disclosures, 19 cornerstone investors collectively hold 28.2549 million H shares, with lock-up periods all ending on December 28, 2026 and official unlocking from December 29, 2026, corresponding to a market value of approximately HKD 639 million based on the offer price. The cornerstone lineup involves Loomis Sayles, GF Fund Management, China Universal Asset Management (Hong Kong), E Fund Management and others.

According to public information, ALEBUND-B (09637.HK) listed on the Main Board of The Stock Exchange of Hong Kong Limited on June 29, 2026 at an offer price of HKD 22.60, with a global offering of 56.7554 million H shares; net proceeds were approximately HKD 1.181 billion; the Hong Kong public offering was 963.56 times subscribed and the international offering 19.77 times subscribed.

In terms of performance, the company disclosed its first interim results after listing in August 2026, posting revenue of RMB 104 million for the first half of 2026, up 761.2% year on year, mainly from license income of RMB 79.30 million recognized under the licensing agreement between AP306 and R1 Therapeutics and sales revenue of RMB 24.80 million from the commercialized product MIRCERA®; the loss for the period was approximately RMB 163 million, narrowed by 22.5% year on year.

HTSC noted that ALEBUND-B is a rare biopharmaceutical company in Hong Kong focused on the research and development of kidney disease drugs; its core pipeline AP301 and AP306 for hyperphosphatemia have read out clinical data, with AP301 having submitted a New Drug Application in China and being in Phase III clinical trials in the United States, and AP306 having entered into an out-licensing partnership with R1 Therapeutics.

Founded in 2018, ALEBUND-B (09637.HK) is an integrated innovative biopharmaceutical company focused on the kidney disease field, building a pipeline around the core clinical needs at various stages of chronic kidney disease, with indications covering hyperphosphatemia, renal anemia, IgA nephropathy and diabetic nephropathy; the company has built its own production base in Yangzhou, Jiangsu, and established a specialized nephrology commercialization team.